A synthesis method for combining a histone deacetylase inhibitor (abbreviatedly referred as HDACi or HDAC inhibitor) SC-027 and a labelling radioactive nuclide gallium-67 or gallium-68 is provided. A labelling precursor DOTA-SC-027 shall be firstly synthesized before combining the HDAC inhibitor SC-027 and the labelling radioactive nuclide gallium-67 or gallium-68. The labelling precursor DOTA-SC-027, which contains a compound of DOTA-NHS-ester (NHS indicating N-hydroxysuccinimide) and the HDAC inhibitor SC-027, is utilized for combining the HDAC inhibitor SC-027 with the labelling radioactive nuclide gallium-67 or gallium-68 so as to produce an imaging compound for the HDAC inhibitor.一種結合組織蛋白去乙醯酶抑制劑(Histone deacetylase inhibitor,以下簡稱HDACi或HDAC抑制劑)SC-027與標誌放射性核種鎵-67或鎵-68之合成方法,其中HDAC抑制劑SC-027 與標誌放射性核種鎵-67或鎵-68結合之前,必須先合成標誌前驅物DOTA-SC-027,其中標誌前驅物DOTA-SC-027係包含羥基丁二酰亞胺 (即DOTA-NHS-ester N-hydroxysuccinimide, 簡稱NHS) 與組織蛋白去乙醯酶抑制劑SC-027之化合物,用以將HDAC抑制劑SC-027 與標誌放射性核種鎵-67或鎵-68結合,以產生組織蛋白去乙醯抑制劑之造影化合物。
